Board of Directors

  • Agneta Edberg

    Chairman

    Alumna from Stockholm School of Economics, Biomedical Analyst
    Chairman

    CEO of Mylan Nordic. Previously: Chief Operating Officer (COO) at Bactiguard AB and COO, VP Senior Venture Manager at LinkMed. CEO of LFF Service AB, The Swedish Pharmaceutical
    Insurance Association. Previous leading positions at Pfizer and Pharmacia, CEO for NM Pharma AB, Cederroth International, Farmos (Orion) AB, and Cilag (J&J) AB.

    Independence: Agneta is independent from the Company, its management and its primary shareholders. Chairman of the Board since 2010.

  • Magnus Nilsson

    Board member

    Doctor Med. Sc. at Uppsala Universitet

    CEO of Xvivo Perfusion from 2011 and before that CEO in Vitrolife since 2003. Before that project leader for preclinical and clinical development, KaroBio AB and Pharmacia & Upjohn AB.

  • Charlotte Edenius

    Board Member

    M.D., Ph.D., Karolinska Institute, Stockholm

    Charlotte Edenius has extensive experience from leading positions in pharmaceutical and biotech companies, including drug discovery and development, regulatory affairs and marketing. She has previously served as Executive Vice President, R&D, Medivir AB; Senior Vice President R&D, Orexo AB; Vice President Research, Biolipox; and in various positions within AstraZeneca Clinical R&D. Charlotte is presently Director of the Boards at Kancera AB, Aptahem AB and SynAct Pharma AB. She holds an MD and PhD from the Karolinska Institutet, Stockholm.

    Independence: Charlotte is independent from the Company, its management and its primary shareholders. Member of the Board since 2016.

  • Martin Lindström

    Board member

    M. Sc. Civil Engineering, B. Sc. Business and Administration

    Martin Lindström, M.Sc., represents the principal owner Loggen Invest AB. He has, since 2008, shown great commitment in working so that Immunicum’s products will reach cancer patients and has contributed to the Company with expertise in economics and law, and by his genuine interest in Immunicum’s business.

    Independence: Martin is independent from the Company and its management but not independent from its primary shareholders. Member of the Board since 2008.

  • Magnus Persson

    Magnus Persson

    Board member

    Physician and an associate Professor in Physiology at the Karolinska Institutet in Stockholm

    Magnus Persson has 15 years of Partner level experience from Venture Capital and has been a Partner in two Life Sciences Venture Capital firms, one with its base in Sweden and with global reach and one in The Bay Area in California. Magnus has a long experience in medicine, life sciences and biotech financing. He has led development teams of Phase II and III programs in the Pharmaceutical Industry. He has founded and led private as well as public biotech and Medtech companies as Chairman of the Board and Director in Europe and USA. All in all, he has more than 90 Board years in the life science industry and has been involved in a dozen IPOs.

    Independence: Magnus is independent from the Company, its management and its primary shareholders. Member of the Board since 2015.

  • Steven Glazer

    Board member

    MD, University of Copenhagen and trained in Internal Medicine.

    Steven Glazer is an experienced healthcare and biotech executive. He has extensive and broad therapeutic area experience including haematology, oncology, haemophiia, HIV, diabetes, allergic and cardiovascular disease from pharmaceutical and biotechnology companies in Europe and United States. He has a track record of successful planning and implementation of development, regulatory and corporate strategies, project and trial plans. Dr Glazer currently holds the position of Chief Medical Officer at Hansa Medical AB and served as Senior Vice President Development at BioInvent AB, Vice President Development at Zealand Pharma and Medical Director at Novo Nordisk. Steven holds a Doctor of Medicine from the University of Copenhagen and trained in Internal Medicine.

    Independence: Steven is independent from the Company and its management and its primary shareholders. Member of the Board since 2016.

  • Kerstin Valinder Strinnholm

    Board member

    Degree from the School of Journalism at the University of Gothenburg.

    Kerstin Valinder Strinnholm is a Business Development advisor in the pharma/biotech field with a degree from the School of Journalism at the University of Gothenburg. Kerstin has over 30 years of international experience in sales, marketing and business development from senior positions at Astra/AstraZeneca and Nycomed Takeda. Other board positions include Camurus AB, Corline Biomedical AB and Cavastor AB.

    Independence: Kerstin is independent from the Company, its management and its primary shareholders. Member of the Board since 2016.